Relyvrio™ (sodium phenylbutyrate/taurursodiol) – New orphan drug approval
September 29, 2022 - The FDA announced the approval of Amylyx Pharmaceuticals’ Relyvrio (sodium phenylbutyrate/taurursodiol), for the treatment of amyotrophic lateral sclerosis (ALS) in adults.
Download PDF
